LabPulse.com staff writersFinancingBluebird Bio secures up to $175M in debt financingBluebird Bio has secured up to $175 million in debt financing with Hercules Capital, having entered into a five-year term loan facility that provides funds in separate tranches.March 18, 2024CollaborationOxford Nanopore, SeqOne to collaborate on sequencing platformOxford Nanopore and genomics firm SeqOne are collaborating on an end-to-end platform for whole-genome nanopore sequencing reads for clinical diagnostic testing.March 18, 2024Artificial IntelligenceMachine-learning model predicts lung and liver cancer through genome sequence changesResearchers have developed a machine-learning approach that may potentially predict early-stage lung or liver cancer by detecting repetitive sequences in the genome.March 15, 2024CollaborationNGeneBio, Genolution to collaborate on automated NGS systemPrecision diagnostics company NGeneBio and molecular diagnostics firm Genolution have signed a memorandum of understanding to develop and launch an automated next-generation sequencing (NGS) system.March 14, 2024GuidelineFDA updates draft guidance for Alzheimer's drug development biomarkersThe U.S. Food and Drug Administration (FDA) has released an updated draft guidance for the use of biomarkers aimed at sponsors and pharmaceutical companies developing drugs intended to treat early Alzheimer's disease.March 14, 2024FinancingZephyr AI closes $111M series A funding roundBiotech startup Zephyr AI announced on Wednesday that it successfully closed a $111 million series A funding round.March 13, 2024StockT2 Biosystems granted Nasdaq listing extensionNasdaq's Hearings Panel has granted T2 Biosystems' request for an extension for continued listing on the stock market subject to T2 complying with Nasdaq's rule for market value of listed securities.March 12, 2024Hereditary DiseaseBluebird Bio signs state Medicaid agreement for SCD gene therapyBluebird Bio has signed its first outcomes-based Medicaid agreement for its sickle-cell disease (SCD) gene therapy Lyfgenia with the state of Michigan.March 11, 2024AgreementPatient Square Capital to acquire NanoString assets for $220MNanoString Technologies has reached a binding agreement with Patient Square Capital in which NanoString will sell substantially all of its assets to the investment firm for $220 million.March 11, 2024Gene expressionGene-based technique shows potential for rapid diagnosticsBiomedical engineers have developed a new gene-based approach which can be used on test strips for rapid, on-the-spot disease detection with accuracy comparable to that of lab-based polymerase chain reaction (PCR) tests.March 7, 2024Page 1 of 336Next PageTop StoriesFinancingBluebird Bio secures up to $175M in debt financingBluebird Bio has secured up to $175 million in debt financing with Hercules Capital, having entered into a five-year term loan facility that provides funds in separate tranches.CollaborationOxford Nanopore, SeqOne to collaborate on sequencing platformArtificial IntelligenceMachine-learning model predicts lung and liver cancer through genome sequence changesResearch ConsortiumInternational consortium launches project to develop next generation of vaccinesCollaborationNGeneBio, Genolution to collaborate on automated NGS system